BPT-331 / Bright Peak Therap, Livzon Pharma - LARVOL DELTA

Bright Peak Therapeutics presents anti-PD-1/IL-2 BPT-331 for cancer immunotherapy (Bioworld) - "Immunocytokines (ICs) engage multiple mechanisms of action by the use of antibodies to deliver cytokine payloads to the surface of the same immune cell, known as cis-signaling. Researchers from Bright Peak Therapeutics AG have developed ICs by using a novel approach based on site-specific chemical conjugation of engineered cytokines to existing nonmodified antibodies."

New molecule • Oncology

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Bright Peak Therapeutics...announced the acceptance of one oral presentation and two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting....Our PD-1/IL-2 ICs induce strong pharmacodynamic effects in vivo, and we are currently optimizing the pharmacological profiles of PD-1-targeted immunocytokines for clinical application....BPT-143 demonstrates the power of our synthetic protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and are exploiting our technology to develop a pipeline of novel designer cytokines and multi-modal immune therapies."

Preclinical • Oncology